Skip to main content

Table 2 Number of positive questionnaire answers and autoantibodies among controls and subjects with undifferentiated connective tissue disease, major rheumatic diseases and no criteria for diagnosis

From: The impact of unrecognized autoimmune rheumatic diseases on the incidence of preeclampsia and fetal growth restriction: a longitudinal cohort study

  Controls n = 597 UCTD n = 131 Major rheumatic diseases n = 68 No criteria for diagnosis n = 150
N. of items N (%) N (%) N (%) N (%)
 1 - 8 (61.1) 8 (11.8) -
 2 - 54 (41.2) 24 (35.3) 87 (58)
 >2 - 69 (52.7) 36 (52.9) 63 (42)
ANA titre
 1:80 24 (4) 42 (32.1) 13 (19.1) 82 (54.6)
 1:160 8 (1.3) 46 (35.1) 16 (23.5) 26 (17.3)
  > 1:160   43 (32.8) 26 (38.2) 11 (7.3)
dsDNA 0 5 (3.8) 8 (11.7) 2 (1.3)
ENA 0 17 (12.9) 22 (32.4) 0
aCLIgG 0 6 (4.6) 10 (14.7) 9 (6)
aCL IgM 1 (0.16) 14 (10.7) 11 (16.2) 22 (14.6)
beta2GP1IgG 0 4 (3.05) 8 (11.7) 8 (5.3)
LAC 0 1 (0.76) 9 (13.2) 0
  1. UCTD undifferentiated connective tissue disease, ANA antinuclear antibodies, dsDNA anti-double stranded DNA, ENA extractable nuclear antigen antibodies, aCL anticardiolipin autoantibodies, beta2GP1 beta2glicoprotein1, LAC lupus anticoagulant